Opc Pharmaceutical JSC (STC:OPC) Debt-to-EBITDA : 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Opc Pharmaceutical JSC Debt-to-EBITDA?

Opc Pharmaceutical JSC STC:OPC Debt-to-EBITDA is 0.00 as of . 20.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Opc Pharmaceutical JSC's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₫0.00 Mil. Opc Pharmaceutical JSC's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₫0.00 Mil. Opc Pharmaceutical JSC's annualized EBITDA for the quarter that ended in . 20 was ₫0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Opc Pharmaceutical JSC's Debt-to-EBITDA or its related term are showing as below:

STC:OPC's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Debt-to-EBITDA only.

Opc Pharmaceutical JSC  (STC:OPC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Opc Pharmaceutical JSC Debt-to-EBITDA Related Terms


Opc Pharmaceutical JSC Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Opc Pharmaceutical JSC's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opc Pharmaceutical JSC Debt-to-EBITDA Chart

Opc Pharmaceutical JSC Annual Data
Trend
Debt-to-EBITDA

Opc Pharmaceutical JSC Quarterly Data
Debt-to-EBITDA

STC:OPC vs IMNPQ, INNV: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Opc Pharmaceutical JSC's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opc Pharmaceutical JSC Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Opc Pharmaceutical JSC's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Opc Pharmaceutical JSC's Debt-to-EBITDA falls into.



Opc Pharmaceutical JSC Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Opc Pharmaceutical JSC's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Opc Pharmaceutical JSC's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (. 20) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
Opc Pharmaceutical JSC (STC:OPC) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Opc Pharmaceutical JSC.
Is Opc Pharmaceutical JSC's Debt-to-EBITDA too high?
Opc Pharmaceutical JSC's current Debt-to-EBITDA is 0.00.
How does Opc Pharmaceutical JSC's Debt-to-EBITDA compare to IMNPQ and INNV?
Opc Pharmaceutical JSC's Debt-to-EBITDA of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Opc Pharmaceutical JSC. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Opc Pharmaceutical JSC's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opc Pharmaceutical JSC stock overvalued right now?
Opc Pharmaceutical JSC (STC:OPC) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Opc Pharmaceutical JSC (STC:OPC), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Opc Pharmaceutical JSC Business Description

Address 1017 Hong Bang Street, Ward 12, District 6, Ho Chi Minh City, VNM
Opc Pharmaceutical JSC operates as a pharmaceutical company. The company is engaged in manufacturing pharmaceutical products originating from medicinal herbs. It offers kidney stone tablets, eucalyptus oil, heart aid capsules, heart tonic, and toothache drops.